Astrazeneca Plc ADR (AZN)

$193.03 +5.87 (3.14%)
Market Cap 290.72B
Revenue (ttm) 54.07B
Net Income (ttm) 7.04B
EPS (ttm) N/A
PE Ratio 20.17
Forward PE 17.99
Profit Margin 13.01%
Debt to Equity Ratio 0.67
Volume 3,116,567
Avg Vol 6,638,534
Day's Range N/A - N/A
Shares Out 1.55B
Stochastic %K 94%
Beta 0.34
Analysts Strong Sell
Price Target $204.33

Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze,...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 44 20 3749 5000
Address:
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom
WallStWireAds
WallStWireAds Jul. 15 at 6:03 PM
$ENTX https://www.benzinga.com/content/60467397/after-crinetics-10-billion-deal-could-entera-bio-be-next-category-defining-oral-peptide-story $CRNX $ERNA $AZN $LLY
0 · Reply
robcarroll
robcarroll Jul. 15 at 3:31 PM
$AZN failure may be a blessing in disguise for $SLS in a bidding war. AZN's Wainua flop is a reminder that even large-caps are exposed when late-stage bets miss - the kind of pipeline pressure that pushes big pharma toward BD to buy back growth. If GPS hits in REGAL, a de-risked AML asset becomes a much more visible acquisition/licensing candidate in exactly that environment. The macro setup makes the "big pharma needs to buy growth" thesis more relevant to $SLS upcoming phase 3 readout. $XBI $IBB https://www.cnbc.com/2026/07/11/astrazenecas-trial-pipeline-pharma-valutaion-stock.html
1 · Reply
Deelam
Deelam Jul. 15 at 2:48 PM
$AZN They only expressed their skepticism. The panel does not consider speculation as a valid reason to keep a company listed, for obvious reasons.
1 · Reply
Deelam
Deelam Jul. 15 at 2:29 PM
$AZN GMRE gave out dozens and dozens of dividends in that time, to the order of about 8.5% per year. He had a very lucrative and successful tenure. The reason the stock has been driven so low has nothing to do with him. He inherited a shit sandwich. Since he became CEO he's penned a definitive merger agreement and is trying to launch an oncology registry to investigate further uses of Ignite's technology. More than Scamro ever did. Do you not understand why Ignite's tech is so (potentially) valuable? It's currently the only predictive tool for HER2 negative patients for $AZN Enhertu ADC drug. It's useful for predicting patient responses to other ADCs as well. As a companion diagnostic, it is literally worth hundreds of millions of dollars. As a predictive tool for ADC development, it could be worth billions.
0 · Reply
Quantumup
Quantumup Jul. 15 at 12:48 PM
Stifel reiterated $CELC Buy-$175~~Sees upside to its current estimates after MGMT suggested it would seek a premium to currently available therapies—expect a solid launch. $RLAY $AZN NVS PFE H.C. Wainwright⬆️ $CELC's PT to $155 from $145 and reiterated its Buy rating. Here's what H.C. Wainwright had to say: https://x.com/Quantumup1/status/2077374448575950886?s=20
0 · Reply
Quantumup
Quantumup Jul. 15 at 12:25 PM
H.C. Wainwright reiterated $SNDX Buy-$40 $KURA $AZN ABBV - RHHBY Here's what H.C. Wainwright said in its note: https://x.com/Quantumup1/status/2077368692682195408?s=20
0 · Reply
KoalaFlipper
KoalaFlipper Jul. 15 at 11:57 AM
$CGEN maybe some good news coming related to $AZN
0 · Reply
Bazziggr
Bazziggr Jul. 14 at 7:59 PM
$AZN $150?
0 · Reply
Makingmillions192
Makingmillions192 Jul. 14 at 1:52 PM
$RHHBY $AMGN $AZN While Big Pharma races to acquire oral GLP-1 delivery tech, this platform developer is about to drop human and next-gen animal datasets that could rewrite the market's tolerability standards. The Late-Summer Data Drop Schedule: Lexaria Bioscience Ticker: LEXX Mid-August 2026 | Animal Study #2 (GLP-1-A26-2) Pharma is watching platform compatibility and PK data for tomorrow's next-gen blockbusters: Eli Lilly's retatrutide and Novo Nordisk's amycretin. Late August / Early September 2026 | Human Study #7 (GLP-1-H26-7) THE MAIN EVENT. Head-to-head 5-week steady-state human data comparing DehydraTECH-semaglutide tablets directly against Wegovy. Pharma is tracking bio-absorption and a projected ~40% reduction in GI side effects. Early September 2026 | Animal Study #1 (GLP-1-A26-1) Pharma is watching alternative novel formulations designed to bypass or improve upon traditional, erratic SNAC-inclusive carriers.
0 · Reply
Merlintrader
Merlintrader Jul. 14 at 12:02 PM
$BIIB Biotech Radar July 14, 2026: Biogen, AstraZeneca, GSK and Evotec — $BIIB, $AZN, $GSK, $EVO https://www.merlintrader.com/biotech-radar-july14-2026/
0 · Reply
Latest News on AZN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN

Tue, 14 Jul 2026 16:54:00 -0400 - 23 hours ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN

Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving AstraZeneca (AZN)

Tue, 14 Jul 2026 10:12:00 -0400 - 1 day ago

Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving AstraZeneca (AZN)

AstraZeneca Secures Licensing Deal for Zegfrovy (AZN)

2026-07-14T11:27:18.000Z - 1 day ago

AstraZeneca Secures Licensing Deal for Zegfrovy (AZN)

AstraZeneca (AZN) Expands Oncology Portfolio with $600M Lung Cancer Drug Acquisition

2026-07-14T09:58:19.000Z - 1 day ago

AstraZeneca (AZN) Expands Oncology Portfolio with $600M Lung Cancer Drug Acquisition

AstraZeneca to acquire rights to develop, commercialize Zegfrovy for $600M

2026-07-14T09:40:33.000Z - 1 day ago

AstraZeneca to acquire rights to develop, commercialize Zegfrovy for $600M

AstraZeneca Enters Exclusive License Deal For Lung Cancer Drug Zegfrovy For Up to $1.5 Billion

Tue, 14 Jul 2026 02:55:00 -0400 - 1 day ago

AstraZeneca Enters Exclusive License Deal For Lung Cancer Drug Zegfrovy For Up to $1.5 Billion

AstraZeneca to license lung cancer drug from China's Dizal Pharmaceutical

Tue, 14 Jul 2026 02:19:59 -0400 - 1 day ago

AstraZeneca to license lung cancer drug from China's Dizal Pharmaceutical

The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions

Mon, 13 Jul 2026 12:25:30 -0400 - 2 days ago

The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions

Alnylam price target raised to $485 from $470 at H.C. Wainwright

2026-07-13T14:50:11.000Z - 2 days ago

Alnylam price target raised to $485 from $470 at H.C. Wainwright

ALNY IONS

AZN Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into AstraZeneca (AZN)

Mon, 13 Jul 2026 10:07:00 -0400 - 2 days ago

AZN Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into AstraZeneca (AZN)

AstraZeneca downgraded to Hold from Buy at HSBC

2026-07-13T09:15:24.000Z - 2 days ago

AstraZeneca downgraded to Hold from Buy at HSBC

FTSE 100 Closes Higher at 10,497.29 as London's Vodafone Surges, EasyJet Takeover Bid Lifts Sentiment

2026-07-13T06:57:50.000Z - 2 days ago

FTSE 100 Closes Higher at 10,497.29 as London's Vodafone Surges, EasyJet Takeover Bid Lifts Sentiment

View post: AstraZeneca erases billions after sobering reveal, AstraZeneca erases billions after sobering reveal

2026-07-12T01:03:00.000Z - 3 days ago

View post: AstraZeneca erases billions after sobering reveal, AstraZeneca erases billions after sobering reveal

AstraZeneca Updates 2030 Sustainability Goals as AI and Emissions Cuts Take Center Stage

Sat, 11 Jul 2026 19:03:01 -0400 - 3 days ago

AstraZeneca Updates 2030 Sustainability Goals as AI and Emissions Cuts Take Center Stage

AstraZeneca Updates 2030 Sustainability Goals as AI and Emissions Cuts Take Center Stage

2026-07-11T23:02:28.000Z - 3 days ago

AstraZeneca Updates 2030 Sustainability Goals as AI and Emissions Cuts Take Center Stage

AstraZeneca's trial flop raises a bigger question: Is its pipeline premium becoming more vulnerable?

Sat, 11 Jul 2026 01:00:01 -0400 - 4 days ago

AstraZeneca's trial flop raises a bigger question: Is its pipeline premium becoming more vulnerable?

Astrazeneca (AZN) Stock Dips While Market Gains: Key Facts

2026-07-10T22:15:05.000Z - 4 days ago

Astrazeneca (AZN) Stock Dips While Market Gains: Key Facts

AstraZeneca's (AZN) Vaccine Influence Under Scrutiny Amid New Administration Nomination

2026-07-10T21:26:18.000Z - 4 days ago

AstraZeneca's (AZN) Vaccine Influence Under Scrutiny Amid New Administration Nomination

AstraZeneca price target lowered to 17,500 GBp from 18,000 GBp at Citi

2026-07-10T15:50:18.000Z - 5 days ago

AstraZeneca price target lowered to 17,500 GBp from 18,000 GBp at Citi

AZN SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving AstraZeneca

Fri, 10 Jul 2026 09:00:00 -0400 - 5 days ago

AZN SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving AstraZeneca

Intellia Therapeutics price target raised to $17 from $12 at Wedbush

2026-07-10T12:06:00.000Z - 5 days ago

Intellia Therapeutics price target raised to $17 from $12 at Wedbush

ALNY IONS NTLA

AstraZeneca price target raised to C$190 from C$180 at Stifel

2026-07-10T11:50:13.000Z - 5 days ago

AstraZeneca price target raised to C$190 from C$180 at Stifel

AstraZeneca Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into AstraZeneca (AZN)

Thu, 09 Jul 2026 20:58:00 -0400 - 5 days ago

AstraZeneca Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into AstraZeneca (AZN)

AstraZeneca PLC (AZN) Shares Fall 5.7% -- What GF Score of 82 Tells Investors

2026-07-09T22:11:16.000Z - 5 days ago

AstraZeneca PLC (AZN) Shares Fall 5.7% -- What GF Score of 82 Tells Investors

AstraZeneca slump weighs on FTSE 100

2026-07-09T21:44:40.000Z - 5 days ago

AstraZeneca slump weighs on FTSE 100

Stocks to Watch: PepsiCo, Salesforce, AstraZeneca

2026-07-09T21:28:49.000Z - 5 days ago

Stocks to Watch: PepsiCo, Salesforce, AstraZeneca

AstraZeneca in £20bn hit after heart disease drug hoped to be a potential blockbuster flops in trials

2026-07-09T21:01:05.000Z - 5 days ago

AstraZeneca in £20bn hit after heart disease drug hoped to be a potential blockbuster flops in trials

Lumentum, Sandisk, Applied Materials, AstraZeneca, and More Stocks That Explain Today’s Market

2026-07-09T20:47:00.000Z - 5 days ago

Lumentum, Sandisk, Applied Materials, AstraZeneca, and More Stocks That Explain Today’s Market

AstraZeneca Shares Sink After Heart Drug Trial Miss. Rare Clinical Setback Tests Investor Confidence

2026-07-09T19:05:49.000Z - 6 days ago

AstraZeneca Shares Sink After Heart Drug Trial Miss. Rare Clinical Setback Tests Investor Confidence

Appeals court upholds win for AstraZeneca in Pfizer patent fight, Reuters says

2026-07-09T18:30:15.000Z - 6 days ago

Appeals court upholds win for AstraZeneca in Pfizer patent fight, Reuters says

PFE

US appeals court upholds win for AstraZeneca in Pfizer cancer drug patent fight

2026-07-09T16:39:07.935Z - 6 days ago

US appeals court upholds win for AstraZeneca in Pfizer cancer drug patent fight

AstraZeneca (AZN) Faces Setback as Phase 3 Study Misses Key Endpoint

2026-07-09T16:14:26.000Z - 6 days ago

AstraZeneca (AZN) Faces Setback as Phase 3 Study Misses Key Endpoint

Ionis Pharmaceuticals price target lowered to $94 from $108 at TD Cowen

2026-07-09T16:00:14.000Z - 6 days ago

Ionis Pharmaceuticals price target lowered to $94 from $108 at TD Cowen

IONS

Is AstraZeneca (AZN) Stock a Buy on Today’s Dip? Here’s What Analysts Have to Say About That

2026-07-09T14:36:08.000Z - 6 days ago

Is AstraZeneca (AZN) Stock a Buy on Today’s Dip? Here’s What Analysts Have to Say About That

IONS

AZN Stock Update: Key Market Insights for Investors

2026-07-09T14:25:46.000Z - 6 days ago

AZN Stock Update: Key Market Insights for Investors

AstraZeneca Slides 9.9% After Heart Drug Trial Misses Late-Stage Goal

2026-07-09T13:29:41.000Z - 6 days ago

AstraZeneca Slides 9.9% After Heart Drug Trial Misses Late-Stage Goal

Morning Movers: Ionis and AstraZeneca sink after trial misses endpoint

2026-07-09T13:05:59.000Z - 6 days ago

Morning Movers: Ionis and AstraZeneca sink after trial misses endpoint

AP AZZ BYRN CRM IONS LEVI PEP

BridgeBio Pharma (BBIO) and Alnylam Pharma (ALNY) Surge After AstraZeneca Trial Setback

2026-07-09T12:55:54.000Z - 6 days ago

BridgeBio Pharma (BBIO) and Alnylam Pharma (ALNY) Surge After AstraZeneca Trial Setback

Why AstraZeneca Crashed 8%, Leading Three Rivals, Including Pfizer, To Jump

2026-07-09T12:54:32.000Z - 6 days ago

Why AstraZeneca Crashed 8%, Leading Three Rivals, Including Pfizer, To Jump

5 Things to Know Before the Stock Market Opens on Thursday

Thu, 09 Jul 2026 08:35:47 -0400 - 6 days ago

5 Things to Know Before the Stock Market Opens on Thursday

UK stocks decline as AstraZeneca tumbles after trial setback

Thu, 09 Jul 2026 08:12:14 -0400 - 6 days ago

UK stocks decline as AstraZeneca tumbles after trial setback

Stocks making the biggest moves premarket: AstraZeneca, PepsiCo, Salesforce, Levi & more

2026-07-09T11:39:45.000Z - 6 days ago

Stocks making the biggest moves premarket: AstraZeneca, PepsiCo, Salesforce, Levi & more

AstraZeneca Stock and Partner Ionis Sink After Trial Failure. Alnylam Soars.

Thu, 09 Jul 2026 07:38:00 -0400 - 6 days ago

AstraZeneca Stock and Partner Ionis Sink After Trial Failure. Alnylam Soars.

London's FTSE 100 slips as Middle East tensions persist, AstraZeneca drags

2026-07-09T11:03:26.095Z - 6 days ago

London's FTSE 100 slips as Middle East tensions persist, AstraZeneca drags

Why Is AstraZeneca Stock (AZN) Falling Today?

2026-07-09T10:35:28.000Z - 6 days ago

Why Is AstraZeneca Stock (AZN) Falling Today?

IONS

AstraZeneca (AZN) Faces Setback in Phase III Cardiomyopathy Trial

2026-07-09T10:25:24.000Z - 6 days ago

AstraZeneca (AZN) Faces Setback in Phase III Cardiomyopathy Trial

AstraZeneca Falls After Wainua Heart Disease Trial Fails

2026-07-09T10:14:18.000Z - 6 days ago

AstraZeneca Falls After Wainua Heart Disease Trial Fails

AstraZeneca (AZN) Shares Plunge Following Trial Setback

2026-07-09T09:55:22.000Z - 6 days ago

AstraZeneca (AZN) Shares Plunge Following Trial Setback

Major drugmaker loses $27 billion in market value after failed trial

Thu, 09 Jul 2026 05:53:00 -0400 - 6 days ago

Major drugmaker loses $27 billion in market value after failed trial

AstraZeneca (AZN) Shares Drop 9% Following Disappointing Clinical Trial Results

2026-07-09T09:50:35.000Z - 6 days ago

AstraZeneca (AZN) Shares Drop 9% Following Disappointing Clinical Trial Results

Ionis, AstraZeneca report CARDIO-TTRansform trial misses primary endpoint

2026-07-09T09:25:31.000Z - 6 days ago

Ionis, AstraZeneca report CARDIO-TTRansform trial misses primary endpoint

IONS

AstraZeneca says CARDIO-TTRansform trial did not meet primary efficacy endpoint

2026-07-09T09:15:32.000Z - 6 days ago

AstraZeneca says CARDIO-TTRansform trial did not meet primary efficacy endpoint

IONS

AstraZeneca shares plunge as Wainua fails late-stage heart disease trial

Jul 9, 2026, 4:49 AM EDT - 6 days ago

AstraZeneca shares plunge as Wainua fails late-stage heart disease trial

AstraZeneca stock dives 9% after heart drug trial misses target

Jul 9, 2026, 3:34 AM EDT - 6 days ago

AstraZeneca stock dives 9% after heart drug trial misses target

AstraZeneca Says Wainua Trial Failed to Meet Primary Goal

Jul 9, 2026, 2:59 AM EDT - 6 days ago

AstraZeneca Says Wainua Trial Failed to Meet Primary Goal

AstraZeneca-Ionis drug fails to meet main goal in late-stage heart disease trial

Jul 9, 2026, 2:12 AM EDT - 6 days ago

AstraZeneca-Ionis drug fails to meet main goal in late-stage heart disease trial

IONS

AstraZeneca, Daiichi near UK pricing deal for breast cancer drug, Bloomberg News reports

Jul 8, 2026, 8:53 AM EDT - 7 days ago

AstraZeneca, Daiichi near UK pricing deal for breast cancer drug, Bloomberg News reports

AstraZeneca, Sino Biopharm Sign Up to $1.9 Billion Respiratory Drug Licensing Deal

Jul 7, 2026, 11:44 PM EDT - 7 days ago

AstraZeneca, Sino Biopharm Sign Up to $1.9 Billion Respiratory Drug Licensing Deal

Hong Kong-listed Sino Biopharma, AstraZeneca sign respiratory drug deal worth up to $1.9 billion

Jul 7, 2026, 6:48 PM EDT - 7 days ago

Hong Kong-listed Sino Biopharma, AstraZeneca sign respiratory drug deal worth up to $1.9 billion

AstraZeneca Transcript: Investor update

Jul 6, 2026, 9:30 AM EDT - 9 days ago

AstraZeneca Transcript: Investor update

AstraZeneca Slides: Investor update

Jul 6, 2026, 9:30 AM EDT - 9 days ago

AstraZeneca Slides: Investor update

AstraZeneca signs CSPC China deal for experimental kidney disease drugs

Jul 2, 2026, 6:16 AM EDT - 13 days ago

AstraZeneca signs CSPC China deal for experimental kidney disease drugs

Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NSCLC

Jul 1, 2026, 9:00 PM EDT - 13 days ago

Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NSCLC

For decades, the only first treatment for one of the deadliest breast cancers was standard chemotherapy. Now there are two newly approved drugs.

Jun 24, 2026, 3:42 PM EDT - 21 days ago

For decades, the only first treatment for one of the deadliest breast cancers was standard chemotherapy. Now there are two newly approved drugs.

GILD

AstraZeneca and YMCA of the USA Announce Landmark Partnership Aimed to Address Gaps in Cancer Care

Jun 24, 2026, 9:00 AM EDT - 21 days ago

AstraZeneca and YMCA of the USA Announce Landmark Partnership Aimed to Address Gaps in Cancer Care

The U.S. has launched a trade investigation into a German plan to cut spending on pharmaceuticals, a move that could result in fresh tariffs

Jun 19, 2026, 7:52 AM EDT - 26 days ago

The U.S. has launched a trade investigation into a German plan to cut spending on pharmaceuticals, a move that could result in fresh tariffs

NVS

U.S. opens tariff probe targeting Germany's drug pricing policies

Jun 19, 2026, 4:47 AM EDT - 26 days ago

U.S. opens tariff probe targeting Germany's drug pricing policies

NVS

The Healthcare M&A Wave

Jun 17, 2026, 12:30 PM EDT - 4 weeks ago

The Healthcare M&A Wave

ABT ALNY AMGN AMRX ANTX BDX BEAM

Ozempic Linked To Lower Risk Of Violence In New Study

Jun 17, 2026, 11:45 AM EDT - 4 weeks ago

Ozempic Linked To Lower Risk Of Violence In New Study

LLY NVO TWST

Drugmakers race to find a place in the next wave of obesity drugs

Jun 13, 2026, 8:00 AM EDT - 4 weeks ago

Drugmakers race to find a place in the next wave of obesity drugs

AMGN NVO LLY

TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer

Jun 12, 2026, 6:44 PM EDT - 4 weeks ago

TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer

BioInvent's BI-1206 Triplet Achieves 83% Response Rate in Refractory NHL with Improved Safety vs. SOC (EHA 2026)

Jun 11, 2026, 2:20 AM EDT - 4 weeks ago

BioInvent's BI-1206 Triplet Achieves 83% Response Rate in Refractory NHL with Improved Safety vs. SOC (EHA 2026)

AstraZeneca's obesity drug shows promise as analysts see upside beyond consensus

Jun 9, 2026, 9:35 AM EDT - 5 weeks ago

AstraZeneca's obesity drug shows promise as analysts see upside beyond consensus

AstraZeneca Transcript: Investor update

Jun 8, 2026, 7:00 PM EDT - 5 weeks ago

AstraZeneca Transcript: Investor update

AstraZeneca Slides: Investor update

Jun 8, 2026, 7:00 PM EDT - 5 weeks ago

AstraZeneca Slides: Investor update

AstraZeneca obesity pill helps patients lose 10.5% of body weight in trial

Jun 8, 2026, 4:16 PM EDT - 5 weeks ago

AstraZeneca obesity pill helps patients lose 10.5% of body weight in trial

AstraZeneca CEO says AI is reshaping drug development — and helping boost the odds of success

Jun 5, 2026, 6:26 PM EDT - 5 weeks ago

AstraZeneca CEO says AI is reshaping drug development — and helping boost the odds of success

NYSE Content Update: AstraZeneca Celebrates Largest Transfer in NYSE History

Jun 5, 2026, 8:55 AM EDT - 5 weeks ago

NYSE Content Update: AstraZeneca Celebrates Largest Transfer in NYSE History

Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6 Trial

Jun 2, 2026, 8:00 AM EDT - 6 weeks ago

Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6 Trial

5 Foreign Stocks That Could Beat The S&P 500

Jun 1, 2026, 2:44 PM EDT - 6 weeks ago

5 Foreign Stocks That Could Beat The S&P 500

ASML BHP HSBC

IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolization-eligible unresectable liver cancer in EMERALD-3 Phase III trial

Jun 1, 2026, 8:00 AM EDT - 6 weeks ago

IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolization-eligible unresectable liver cancer in EMERALD-3 Phase III trial

AstraZeneca Transcript: Investor update

Jun 1, 2026, 8:00 AM EDT - 6 weeks ago

AstraZeneca Transcript: Investor update

AstraZeneca Slides: Investor update

Jun 1, 2026, 8:00 AM EDT - 6 weeks ago

AstraZeneca Slides: Investor update

BioInvent to Host a KOL Event in Stockholm on June 11, 2026, to Discuss Updated BI-1206 & BI-1808 Data in Hematology

Jun 1, 2026, 5:20 AM EDT - 6 weeks ago

BioInvent to Host a KOL Event in Stockholm on June 11, 2026, to Discuss Updated BI-1206 & BI-1808 Data in Hematology

IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer

May 28, 2026, 9:18 PM EDT - 6 weeks ago

IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer

US FDA extends review of AstraZeneca's experimental breast cancer pill

May 27, 2026, 2:23 AM EDT - 7 weeks ago

US FDA extends review of AstraZeneca's experimental breast cancer pill

How Big Pharma Is Turning Industrial Heat Into A Strategic Asset

May 26, 2026, 9:41 AM EDT - 7 weeks ago

How Big Pharma Is Turning Industrial Heat Into A Strategic Asset

Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates

May 22, 2026, 9:30 AM EDT - 7 weeks ago

Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates

AstraZeneca to showcase Phase III data in liver, breast and bladder cancers and potential first-in-class rare disease therapy at ASCO 2026

May 22, 2026, 7:00 AM EDT - 7 weeks ago

AstraZeneca to showcase Phase III data in liver, breast and bladder cancers and potential first-in-class rare disease therapy at ASCO 2026

EU regulator recommends positive opinion of AstraZeneca's experimental breast cancer drug

May 22, 2026, 6:45 AM EDT - 7 weeks ago

EU regulator recommends positive opinion of AstraZeneca's experimental breast cancer drug

US Supreme Court rebuffs pharma challenge to Biden-era drug price

May 18, 2026, 9:44 AM EDT - 2 months ago

US Supreme Court rebuffs pharma challenge to Biden-era drug price

BMY NVO NVS

BAXFENDY approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension

May 18, 2026, 7:00 AM EDT - 2 months ago

BAXFENDY approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension

AstraZeneca Gets U.S. Approval for Hypertension Drug

May 18, 2026, 2:13 AM EDT - 2 months ago

AstraZeneca Gets U.S. Approval for Hypertension Drug

AstraZeneca's blood pressure drug wins U.S. approval

May 18, 2026, 2:01 AM EDT - 2 months ago

AstraZeneca's blood pressure drug wins U.S. approval

AstraZeneca's Imfinzi with pre-surgery drug boosts survival in bladder cancer trial

May 14, 2026, 2:59 AM EDT - 2 months ago

AstraZeneca's Imfinzi with pre-surgery drug boosts survival in bladder cancer trial

Owkin to Build AI Agents as Part of a Multi-Year K Pro License Agreement With AstraZeneca

May 13, 2026, 1:00 AM EDT - 2 months ago

Owkin to Build AI Agents as Part of a Multi-Year K Pro License Agreement With AstraZeneca

WallStWireAds
WallStWireAds Jul. 15 at 6:03 PM
$ENTX https://www.benzinga.com/content/60467397/after-crinetics-10-billion-deal-could-entera-bio-be-next-category-defining-oral-peptide-story $CRNX $ERNA $AZN $LLY
0 · Reply
robcarroll
robcarroll Jul. 15 at 3:31 PM
$AZN failure may be a blessing in disguise for $SLS in a bidding war. AZN's Wainua flop is a reminder that even large-caps are exposed when late-stage bets miss - the kind of pipeline pressure that pushes big pharma toward BD to buy back growth. If GPS hits in REGAL, a de-risked AML asset becomes a much more visible acquisition/licensing candidate in exactly that environment. The macro setup makes the "big pharma needs to buy growth" thesis more relevant to $SLS upcoming phase 3 readout. $XBI $IBB https://www.cnbc.com/2026/07/11/astrazenecas-trial-pipeline-pharma-valutaion-stock.html
1 · Reply
Deelam
Deelam Jul. 15 at 2:48 PM
$AZN They only expressed their skepticism. The panel does not consider speculation as a valid reason to keep a company listed, for obvious reasons.
1 · Reply
Deelam
Deelam Jul. 15 at 2:29 PM
$AZN GMRE gave out dozens and dozens of dividends in that time, to the order of about 8.5% per year. He had a very lucrative and successful tenure. The reason the stock has been driven so low has nothing to do with him. He inherited a shit sandwich. Since he became CEO he's penned a definitive merger agreement and is trying to launch an oncology registry to investigate further uses of Ignite's technology. More than Scamro ever did. Do you not understand why Ignite's tech is so (potentially) valuable? It's currently the only predictive tool for HER2 negative patients for $AZN Enhertu ADC drug. It's useful for predicting patient responses to other ADCs as well. As a companion diagnostic, it is literally worth hundreds of millions of dollars. As a predictive tool for ADC development, it could be worth billions.
0 · Reply
Quantumup
Quantumup Jul. 15 at 12:48 PM
Stifel reiterated $CELC Buy-$175~~Sees upside to its current estimates after MGMT suggested it would seek a premium to currently available therapies—expect a solid launch. $RLAY $AZN NVS PFE H.C. Wainwright⬆️ $CELC's PT to $155 from $145 and reiterated its Buy rating. Here's what H.C. Wainwright had to say: https://x.com/Quantumup1/status/2077374448575950886?s=20
0 · Reply
Quantumup
Quantumup Jul. 15 at 12:25 PM
H.C. Wainwright reiterated $SNDX Buy-$40 $KURA $AZN ABBV - RHHBY Here's what H.C. Wainwright said in its note: https://x.com/Quantumup1/status/2077368692682195408?s=20
0 · Reply
KoalaFlipper
KoalaFlipper Jul. 15 at 11:57 AM
$CGEN maybe some good news coming related to $AZN
0 · Reply
Bazziggr
Bazziggr Jul. 14 at 7:59 PM
$AZN $150?
0 · Reply
Makingmillions192
Makingmillions192 Jul. 14 at 1:52 PM
$RHHBY $AMGN $AZN While Big Pharma races to acquire oral GLP-1 delivery tech, this platform developer is about to drop human and next-gen animal datasets that could rewrite the market's tolerability standards. The Late-Summer Data Drop Schedule: Lexaria Bioscience Ticker: LEXX Mid-August 2026 | Animal Study #2 (GLP-1-A26-2) Pharma is watching platform compatibility and PK data for tomorrow's next-gen blockbusters: Eli Lilly's retatrutide and Novo Nordisk's amycretin. Late August / Early September 2026 | Human Study #7 (GLP-1-H26-7) THE MAIN EVENT. Head-to-head 5-week steady-state human data comparing DehydraTECH-semaglutide tablets directly against Wegovy. Pharma is tracking bio-absorption and a projected ~40% reduction in GI side effects. Early September 2026 | Animal Study #1 (GLP-1-A26-1) Pharma is watching alternative novel formulations designed to bypass or improve upon traditional, erratic SNAC-inclusive carriers.
0 · Reply
Merlintrader
Merlintrader Jul. 14 at 12:02 PM
$BIIB Biotech Radar July 14, 2026: Biogen, AstraZeneca, GSK and Evotec — $BIIB, $AZN, $GSK, $EVO https://www.merlintrader.com/biotech-radar-july14-2026/
0 · Reply
MyStockHarbor
MyStockHarbor Jul. 14 at 8:11 AM
$AZN aren’t playing around are they? They just dropped a $1.5B licensing deal for Zegfrovy. Lung cancer drug to try take it global as the first line treatment, instead of first line chemo.
0 · Reply
TalkMarkets
TalkMarkets Jul. 13 at 3:44 PM
The FTSE 100 Finish Line - Monday, July 13 $BP $SHEL $VOD $AZN https://talkmarkets.com/article/the-ftse-100-finish-line---monday-july-13-1783957441
0 · Reply
Quantumup
Quantumup Jul. 13 at 11:25 AM
H.C. Wainwright⬆️ $BBIO to $120, reit'd Buy/said~~Late last week, $IONS and its partner $AZN reported that the CARDIO-TTRansform Phase 3 trial of their agent Wainua (eplontersen) in patients with ATTR-CM did not meet the primary efficacy endpoint. ALNY PFE H.C. Wainwright added—From our vantage point, the possibility that eplontersen may not emerge as a commercial rival to acoramidis may represent an incremental positive for BridgeBio. We reiterate our Buy rating while raising our 12-month price target to $120 from the prior $110 per share. This reflects what we consider to be the reduced degree of equity dilution based on the terms of the preferred stock financing.
0 · Reply
BlazeBear5128
BlazeBear5128 Jul. 12 at 3:52 PM
$AZN trial miss puts the pipeline premium under the microscope. When a key study flops, the market starts asking whether the valuation already priced in too much future upside. For a name like AstraZeneca, it’s not just one data point — it’s about how much trust is left in the pipeline story.
0 · Reply
Bazziggr
Bazziggr Jul. 12 at 2:35 PM
$AZN geopolitical risk...More drop ahead
0 · Reply
Jhoooon
Jhoooon Jul. 11 at 10:00 PM
$AZN
0 · Reply
Jhoooon
Jhoooon Jul. 11 at 10:00 PM
$AZN
0 · Reply
Jhoooon
Jhoooon Jul. 11 at 10:00 PM
$AZN
0 · Reply
Jhoooon
Jhoooon Jul. 11 at 10:00 PM
$AZN
0 · Reply
Jhoooon
Jhoooon Jul. 11 at 9:59 PM
$AZN
0 · Reply
Jhoooon
Jhoooon Jul. 11 at 9:58 PM
$AZN glad I added a lot here
0 · Reply
OctahedronOmega
OctahedronOmega Jul. 11 at 4:01 PM
$TECX is a high-risk binary here IMO, especially after $AZN DC’d a similar molecule. Early hemodynamic data looks encouraging, but this disease has been tough to translate into real clinical benefit like 6MWD. I’ve seen this setup before — data can look good, but the market usually wants proof it moves outcomes.
0 · Reply